Study finds technique offers better quality product than traditional drying techniques
PRINCETON, NEW JERSEY (October 04, 2023) — A joint study by Inaedis, Inc., a new plaform biotechnology company, and researchers from one of the top 10 largest pharmaceutical companies, found that Inaedis’s proprietary rapid room temperature aerosol dehydration (RTAD) methods offered improved outcomes on protein degradation and aerosol performance over traditional drying technologies. The paper in the Journal of Pharmaceutical Sciences was based on a 2023 trial at Princeton University.
“RTAD is a breakthrough biotechnology, and this peer-reviewed study proves it,” said Inaedis founder and CEO Dr. Maxsim Mezhericher. “We’re excited to keep developing our methodology, which will revolutionize how biologics and life-saving drugs are developed, delivered, and distributed.”
The blind validation study was performed for thermally-sensitive liquid fragment antigen-binding (FAB) formulations supplied by AstraZeneca. Inaedis used its proprietary RTAD technology to turn these liquid formulations into powders, which were sent to AstraZeneca for analysis. The results of the analysis showed the RTAD samples were of a significantly higher quality than spray-dried sample controls.
“Traditional thermal stabilization technologies struggle to maintain the integrity of biologic drugs,” said Inaedis founder Professor Howard A. Stone. “RTAD is a viable alternative, and it has the capacity to fundamentally improve vaccine powderization and save countless lives.
The co-authors include AstraZeneca’s Sadegh Poozesh, Zehao Pan, Uzair Chaudhary, and Prakash Manikwar and Inaedis’s Dr. Maksim Mezhericher and Prof. Howard A. Stone.
Inaedis, Inc.
Inaedis, Inc. is a spin-out company from Princeton University developing a pharmaceutical platform changing the future of drug development, delivery, and distribution by powderizing life-saving vaccines and biologics.
First developed by Princeton scientists during the Covid-19 pandemic, our goal is to give everyone access to the miracles of modern medicine. Our proprietary Rapid Room-Temperature Dehydration (RTAD) platform technology finally solves the global dilemma posed by the thermal stabilization requirements of life-saving heat and freeze-sensitive vaccines and biologics.
Inaedis is led by its founders: CEO Dr. Maksim Mezhericher and Prof. Howard A. Stone and is backed by Roadrunner Venture Studios and Princeton Innovation Center.
Media Contact: Maksim Mezhericher, maksim@inaedis.com